American Medical Association to Issue First New Code for Psychedelic Therapies

Stock Information for COMPASS Pathways Plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About COMPASS Pathways Plc

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
Compass Pathways to Participate in Stifel Virtual CNS Forum
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights
Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.